{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:12:46Z","timestamp":1783440766067,"version":"3.54.6"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11899-025-00765-y","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:01:21Z","timestamp":1764745281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Evolving Therapeutic Landscape of Richter Transformation"],"prefix":"10.1007","volume":"20","author":[{"given":"Henry","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"6","key":"765_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061857","volume":"15","author":"R Briski","year":"2023","unstructured":"Briski R, Taylor J. Treatment of Richter transformation of chronic lymphocytic leukemia in the modern era. Cancers (Basel). 2023;15(6):1857. https:\/\/doi.org\/10.3390\/cancers15061857.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"765_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/cancers17060943","volume":"17","author":"T Jain","year":"2025","unstructured":"Jain T, Heyman B. Updates on the treatment of richter\u2019s syndrome, including novel combination approaches. Cancers (Basel). 2025;17(6):943. https:\/\/doi.org\/10.3390\/cancers17060943.","journal-title":"Cancers (Basel)"},{"issue":"20","key":"765_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205141","volume":"13","author":"T Tadmor","year":"2021","unstructured":"Tadmor T, Levy I. Richter transformation in chronic lymphocytic leukemia: update in the era of novel agents. Cancers (Basel). 2021;13(20):5141. https:\/\/doi.org\/10.3390\/cancers13205141.","journal-title":"Cancers (Basel)"},{"key":"765_CR4","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","volume":"123","author":"SA Parikh","year":"2014","unstructured":"Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014;123:1647\u201357. https:\/\/doi.org\/10.1182\/blood-2013-11-516229.","journal-title":"Blood"},{"issue":"3","key":"765_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood.2024028064","volume":"146","author":"AS Kittai","year":"2025","unstructured":"Kittai AS, Marchetti M, Al-Sawaf O, Benjamini O, Danilov AV, Davids MS, et al. International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations. Blood. 2025;146(3):291\u2013303. https:\/\/doi.org\/10.1182\/blood.2024028064.","journal-title":"Blood"},{"key":"765_CR6","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","volume":"117","author":"D Rossi","year":"2011","unstructured":"Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117:3391\u2013401.","journal-title":"Blood"},{"key":"765_CR7","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","volume":"31","author":"Z Mao","year":"2007","unstructured":"Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of richter\u2019s transformation\u2026 represent 2 different pathways of disease evolution. Am J Surg Pathol. 2007;31:1605\u201314.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"765_CR8","first-page":"11","volume":"142","author":"E Parry","year":"2023","unstructured":"Parry E, Hacken ET, Wu CJ. Richter syndrome: novel insights into the biology of transformation. Blood. 2023;142(1):11\u201322.","journal-title":"Blood"},{"key":"765_CR9","unstructured":"Thompson P, Siddiqi T et al. Hematol Am Soc Hematol Educ Program.2022(1): 329\u201336."},{"issue":"11","key":"765_CR10","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/bloodadvances.2024015594","volume":"9","author":"A Barrett","year":"2025","unstructured":"Barrett A, Harris C, Eyre T. Clonal relatedness as a prognostic marker in Richter transformation\u2026 a systematic review. Blood Adv. 2025;9(11):2773\u201380.","journal-title":"Blood Adv"},{"key":"765_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5603\/ahp.98365","volume":"55","author":"O So\u015bnia","year":"2024","unstructured":"So\u015bnia O, Pu\u0142a B. Update on management of diffuse large B-cell lymphoma Richter\u2019s transformation. Acta Haematol Pol. 2024;55:97\u2013107. https:\/\/doi.org\/10.5603\/ahp.98365.","journal-title":"Acta Haematol Pol"},{"key":"765_CR12","doi-asserted-by":"publisher","unstructured":"Ryan CE, Davids MS. Practical management of Richter transformation in 2023 and Beyond. American society of clinical oncology educational book. 2023:43:e390804. https:\/\/doi.org\/10.1200\/EDBK_390804","DOI":"10.1200\/EDBK_390804"},{"issue":"12","key":"765_CR13","doi-asserted-by":"publisher","first-page":"E239","DOI":"10.1002\/ajh.23841","volume":"89","author":"P Langerbeins","year":"2014","unstructured":"Langerbeins P, Busch R, Hallek M, Eichhorst B, Cramer P, Bahlo J. Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia with Richter transformation. Am J Hematol. 2014;89(12):E239\u201343. https:\/\/doi.org\/10.1002\/ajh.23841.","journal-title":"Am J Hematol"},{"issue":"3","key":"765_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2019.224121","volume":"105","author":"Y Wang","year":"2019","unstructured":"Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2019;105(3):765\u201373. https:\/\/doi.org\/10.3324\/haematol.2019.224121.","journal-title":"Haematologica"},{"issue":"2","key":"765_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.15035","volume":"180","author":"KA Rogers","year":"2017","unstructured":"Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, et al. A single\u2010institution retrospective cohort study of first\u2010line R\u2010EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2017;180(2):259\u201366. https:\/\/doi.org\/10.1111\/bjh.15035.","journal-title":"Br J Haematol"},{"key":"765_CR16","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Plymouth Meeting (PA): NCCN. 2025. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480"},{"key":"765_CR17","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1182\/bloodadvances.2023012080","volume":"8","author":"PJ Hampel","year":"2024","unstructured":"Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, et al. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024;8:2342\u201350.","journal-title":"Blood Adv"},{"key":"765_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11899-023-00721-8","volume":"19","author":"A Bajwa","year":"2024","unstructured":"Bajwa A, Habib A, Kittai AS. Treatment of Richter\u2019s transformation with novel therapies. Curr Hematol Malig Rep. 2024;19:45\u201355. https:\/\/doi.org\/10.1007\/s11899-023-00721-8.","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"765_CR19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia. JAMA. 2023;329:918. https:\/\/doi.org\/10.1001\/jama.2023.1946.","journal-title":"JAMA"},{"issue":"5","key":"765_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood.2021011386","volume":"139","author":"MS Davids","year":"2022","unstructured":"Davids MS, Rogers KA, Tyekucheva S, et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022;139(5):686\u20139. https:\/\/doi.org\/10.1182\/blood.2021011386.","journal-title":"Blood"},{"issue":"S2","key":"765_CR21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/hon.3164_343","volume":"41","author":"MS Davids","year":"2023","unstructured":"Davids MS, Rogers KA, Jain N, et al. Initial results of a multicenter phase 2 study of venetoclax in combination with R\u2010CHOP (VR\u2010CHOP) for patients with Richter Syndrome. Hematol Oncol. 2023;41(S2):466\u20138. https:\/\/doi.org\/10.1002\/hon.3164_343.","journal-title":"Hematol Oncol"},{"issue":"10","key":"765_CR22","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S1470-2045(24)00396-6","volume":"25","author":"A Tedeschi","year":"2024","unstructured":"Tedeschi A, Frustaci AM, Condoluci A, et al. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(10):1298\u2013309. https:\/\/doi.org\/10.1016\/S1470-2045(24)00396-6.","journal-title":"Lancet Oncol"},{"key":"765_CR23","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","volume":"125","author":"M Tsang","year":"2015","unstructured":"Tsang M, Shanafelt TD, Call TG, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015;125:1676\u20138. https:\/\/doi.org\/10.1182\/blood-2014-12-610782.","journal-title":"Blood"},{"issue":"10","key":"765_CR24","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","volume":"7","author":"N Jain","year":"2023","unstructured":"Jain N, Senapati, Thakral B, et al. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023;7(10):1958\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2022008790.","journal-title":"Blood Adv"},{"key":"765_CR25","doi-asserted-by":"publisher","unstructured":"Tadmor T, Benjamini O, GoldschmidT N et al. Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter\u2019s Syndrome-Givers Regimen. Blood.2024.144 (Supplement 1):1862. https:\/\/doi.org\/10.1182\/blood-2024-205236","DOI":"10.1182\/blood-2024-205236"},{"issue":"4","key":"765_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000870","volume":"7","author":"C Tam","year":"2023","unstructured":"Tam C, Munoz J, Cull G, et al. Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia. Hemasphere. 2023;7(4):e870. https:\/\/doi.org\/10.1097\/HS9.0000000000000870.","journal-title":"Hemasphere"},{"issue":"1","key":"765_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","volume":"30","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Ligtvoet R, Rocrecht S, et al. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. Nat Med. 2024;30(1):240\u20138. https:\/\/doi.org\/10.1038\/s41591-023-02722-9.","journal-title":"Nat Med"},{"issue":"12","key":"765_CR28","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","volume":"8","author":"TA Eyre","year":"2021","unstructured":"Eyre TA, Izumi R, Hekimian A, et al. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001) analysis of the Richter transformation cohort of an open-label, single-arm, phase 1\u20132 study. Lancet Haematol. 2021;8(12):e912\u201321. https:\/\/doi.org\/10.1016\/S2352-3026(21)00305-7.","journal-title":"Lancet Haematol"},{"issue":"1","key":"765_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/s12885-019-5717-y","volume":"19","author":"N Appleby","year":"2019","unstructured":"Appleby N, Eyre T, Caves M, et al. The STELLAR trial protocol: a prospective multicentre trial for richter\u2019s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. BMC Cancer. 2019;19(1):471. https:\/\/doi.org\/10.1186\/s12885-019-5717-y.","journal-title":"BMC Cancer"},{"issue":"9","key":"765_CR30","doi-asserted-by":"publisher","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","volume":"11","author":"WG Wierda","year":"2024","unstructured":"Wierda WG, Shah NN, Cheah CY, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study. Lancet Haematol. 2024;11(9):e682\u201392. https:\/\/doi.org\/10.1016\/S2352-3026(24)00172-8.","journal-title":"Lancet Haematol"},{"issue":"Suppl 2","key":"765_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70064","volume":"43","author":"N Javidi-Sharifi","year":"2025","unstructured":"Javidi-Sharifi N, Davids MS. Advances in the management of relapsed\/refractory CLL and Richter transformation. Hematologist Oncol. 2025;43(Suppl 2):e70064. https:\/\/doi.org\/10.1002\/hon.70064.","journal-title":"Hematologist Oncol"},{"key":"765_CR32","unstructured":"NCT05536349. Time-limited triplet combination of Pirtobrutinib, Venetoclax, and obinutuzumab for patients with Treatment-na\u00efve chronic lymphocytic leukemia (CLL) or Richter transformation (RT). Accessed at clinicaltrials.gov."},{"key":"765_CR33","unstructured":"NCT04728893. Efficacy and safety of Nemtabrutinib (MK-1026) in participants with hematologic malignancies (MK-1026-003). Accessed at clinicaltrials.gov."},{"key":"765_CR34","unstructured":"NCT06863402. Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype. Accessed at clinicaltrials.gov."},{"issue":"3","key":"765_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030557","volume":"17","author":"RT Salvaris","year":"2025","unstructured":"Salvaris RT, Brennan J, Lewis KL. BTK is the target that keeps on giving: a review of BTK-degrader drug development, clinical data, and future directions in CLL. Cancers (Basel). 2025;17(3):557. https:\/\/doi.org\/10.3390\/cancers17030557.","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1","key":"765_CR36","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1182\/blood-2023-180109","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour JF, Cheah CY, Parrondo R, Thompson MC, Stevens DA, Lasica M, et al. First results from a phase 1, first-in-human study of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory B-cell malignancies (BGB-16673-101). Blood. 2023;142(Suppl 1):4401. https:\/\/doi.org\/10.1182\/blood-2023-180109.","journal-title":"Blood"},{"issue":"Suppl 1","key":"765_CR37","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/blood-2024-199116","volume":"144","author":"MC Thompson","year":"2024","unstructured":"Thompson MC, Parrondo RD, Frustaci AM, Allan JN, Ghia P, Mocanu I, et al. Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study. Blood. 2024;144(Suppl 1):885. https:\/\/doi.org\/10.1182\/blood-2024-199116.","journal-title":"Blood"},{"key":"765_CR38","unstructured":"Tam CS. Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study. Accessed at https:\/\/www.onclive.com\/view\/preliminary-efficacy-and-safety-of-the-bruton-tyrosine-kinase-degrader-bgb-16673-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-results-from-the-phase-1-cadance-101-study"},{"key":"765_CR39","first-page":"12","volume-title":"ASH 2024; 2024 Jun","author":"MC Thompson","year":"2024","unstructured":"Thompson MC, Parrondo RD, Frustaci AM, et al. Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic Leukemia\/Small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study. ASH 2024; 2024 Jun. San Diego, CA: American Society of Hematology; 2024. pp. 12\u20135."},{"key":"765_CR40","unstructured":"NCT04830137. A study of NX-2127 in adults with Relapsed\/ refractory B-cell malignancies. Accessed at clinicaltrials.gov."},{"key":"765_CR41","unstructured":"NCT05131022. A study of NX-5948 in adults with Relapsed\/ refractory B-cell malignancies. Accessed at clinicaltrials.gov."},{"issue":"Supplement 1","key":"765_CR42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184835","volume":"142","author":"C Pan","year":"2023","unstructured":"Pan C, Gururaja TL, Li H, et al. Abbv-101, a highly potent and selective clinical stage Bruton tyrosine kinase degrader for the treatment of B-cell malignancies. Blood. 2023;142(Supplement 1):1887. https:\/\/doi.org\/10.1182\/blood-2023-184835.","journal-title":"Blood"},{"issue":"7","key":"765_CR43","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","volume":"42","author":"R He","year":"2018","unstructured":"He R, Ding W, Viswanatha DS, Chen D, Shi M, Van Dyke D, et al. PD-1 expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell Richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness. Am J Surg Pathol. 2018;42(7):843\u201354. https:\/\/doi.org\/10.1097\/PAS.0000000000001077.","journal-title":"Am J Surg Pathol"},{"key":"765_CR44","doi-asserted-by":"publisher","unstructured":"Michot JM, Armand P, Ding W, et al. KEYNOTE-170: phase 2 study of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS). Ann Oncol. 2016;27(8). https:\/\/doi.org\/10.1093\/annonc\/mdw525.","DOI":"10.1093\/annonc\/mdw525"},{"issue":"2","key":"765_CR45","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1111\/bjh.16762","volume":"190","author":"P Armand","year":"2020","unstructured":"Armand P, Murawski N, Molin D, et al. Pembrolizumab in relapsed or refractory Richter syndrome. Br J Haematol. 2020;190(2):e117-20. https:\/\/doi.org\/10.1111\/bjh.16762.","journal-title":"Br J Haematol"},{"key":"765_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7050","author":"Y Wang","year":"2024","unstructured":"Wang Y, LaPlant BR, Parikh SA, et al. Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL). J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7050.","journal-title":"J Clin Oncol"},{"key":"765_CR47","unstructured":"NCCN Guidelines. Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, version 3.2025."},{"key":"765_CR48","doi-asserted-by":"publisher","unstructured":"Othman T, Frankel P, Allen P, et al. Atezolizumab combined with Immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica. 2025;110(1). https:\/\/doi.org\/10.3324\/haematol.2024.285185.","DOI":"10.3324\/haematol.2024.285185"},{"key":"765_CR49","unstructured":"NCT03892044. Duvelisib and nivolumab in treating patients with Richter syndrome or transformed follicular lymphoma. Accessed at clinicaltrials.gov."},{"key":"765_CR50","unstructured":"NCT05672173. Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter\u2019s Transformation. Accessed at clinicaltrials.gov."},{"key":"765_CR51","unstructured":"NCT03884998. Copanlisib and Nivolumab in Treating Patients With Richter\u2019s Transformation or Transformed Indolent Non-Hodgkin Lymphoma. Accessed at clinicaltrials.gov."},{"key":"765_CR52","unstructured":"NCT05388006, Acalabrutinib. Venetoclax and durvalumab for the treatment of Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Accessed at clinicaltrials.gov."},{"issue":"1","key":"765_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/antib11010016","volume":"11","author":"R Tavarozzi","year":"2022","unstructured":"Tavarozzi R, Manzato E. The role of bispecific antibodies in Non-Hodgkin\u2019s lymphoma: from structure to prospective clinical use. Antibodies. 2022;11(1):16. https:\/\/doi.org\/10.3390\/antib11010016.","journal-title":"Antibodies"},{"issue":"4","key":"765_CR54","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.pathol.2022.12.354","volume":"55","author":"SE Hussein","year":"2023","unstructured":"Hussein SE, Medeiros LJ, Lyapichev KA, et al. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023;55(4):514\u201324. https:\/\/doi.org\/10.1016\/j.pathol.2022.12.354.","journal-title":"Pathology"},{"issue":"Supplement 1","key":"765_CR55","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1182\/blood-2022-159695","volume":"140","author":"R Guieze","year":"2022","unstructured":"Guieze R, Ysebaert L, Roos-Weil D, et al. Blinatumomab for patients with Richter syndrome: final results of the phase 2 Blinart trial from the Filo group. Blood. 2022;140(Supplement 1):6631\u20132.","journal-title":"Blood"},{"issue":"1","key":"765_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51264-2","volume":"15","author":"R Guieze","year":"2024","unstructured":"Guieze R, Ysebaert L, Roos-Weil D, et al. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial. Nat Commun. 2024;15(1):6822. https:\/\/doi.org\/10.1038\/s41467-024-51264-2.","journal-title":"Nat Commun"},{"key":"765_CR57","doi-asserted-by":"crossref","unstructured":"Carlo-Stella C, Hutchings M, Offner F, Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation. Hematol Oncol. 2023;41(S2):63-5. [Abstract]","DOI":"10.1002\/hon.3163_28"},{"key":"765_CR58","doi-asserted-by":"crossref","unstructured":"Kater AP, Janssens A, Eradat H, et al. Epcoritamab induces deep responses in patients with Richter transformation (RT): primary results from the EPCORE-CLL1 trial. Clin Lymphoma Myeloma Leuk. 2024;24(Supplement 1):S350-S351. [Abstract]","DOI":"10.1016\/S2152-2650(24)01274-6"},{"key":"765_CR59","doi-asserted-by":"crossref","unstructured":"Kater AP, Janssens A, Eradat H, et al. Epcoritamab Monotherapy in Patients with First-Line Richter\u2019s Transformation: 2-Year Follow-Up Results From the Phase 1b\/2 EPCORE CLL-1 Clinical Trial. iwCLL 2025; Oral Abstract 1606. Boston, MA, USA; 2025","DOI":"10.1182\/blood-2025-1017"},{"key":"765_CR60","unstructured":"Deutsche CLL, Studiengruppe. CLL-RT2. A prospective, open-label, randomized, multicenter phase III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation. Accessed September 24, 2025. https:\/\/www.dcllsg.com\/cll-rt2\/"},{"key":"765_CR61","unstructured":"ClinicalTrials.gov. Evaluation of treatment by glofitamab in combination with rituximab or obinutuzumab plus CHOP in patients with Richter syndrome (NCT06186648). Available from: https:\/\/clinicaltrials.gov\/study\/NCT06186648"},{"key":"765_CR62","unstructured":"ClinicalTrials.gov. CHOP plus mosunetuzumab as first line in patients with Richter\u2019s syndrome: a phase II study of the Spanish Group of CLL (NCT06926205). Available from: https:\/\/clinicaltrials.gov\/study\/NCT06926205"},{"key":"765_CR63","unstructured":"ClinicalTrials.gov. A phase 2 study of glofitamab as monotherapy or in combination with polatuzumab vedotin, pirtobrutinib, or atezolizumab in Richter\u2019s transformation (NCT06043674). Available from: https:\/\/clinicaltrials.gov\/study\/NCT06043674"},{"key":"765_CR64","unstructured":"ClinicalTrials.gov. Zanubrutinib in combination with odronextamab for the treatment of patients with Richter\u2019s transformation (NCT06735664). Available from: https:\/\/clinicaltrials.gov\/study\/NCT06735664"},{"issue":"10402","key":"765_CR65","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study. Lancet. 2023;402(10402):641\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(23)01052-8.","journal-title":"Lancet"},{"issue":"17","key":"765_CR66","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1200\/JCO.24.00033","volume":"42","author":"AS Kittai","year":"2024","unstructured":"Kittai AS, Bond D, Huang Y, et al. Anti-CD19 chimeric antigen receptor T-cell herapy for Richter transformation: an international, multicenter, retrospective study. J Clin Oncol. 2024;42(17):2071\u20139. https:\/\/doi.org\/10.1200\/JCO.24.00033.","journal-title":"J Clin Oncol"},{"key":"765_CR67","doi-asserted-by":"publisher","unstructured":"Nadiminti KV, Ahn KW, Patel J, et al. Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis.\u00a0Transplant Cell Ther. 2025:S2666-6367(25)01334-X. Published online August. 2025;5. https:\/\/doi.org\/10.1016\/j.jtct.2025.07.021.","DOI":"10.1016\/j.jtct.2025.07.021"},{"issue":"Supplement 1","key":"765_CR68","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2024-208539","volume":"144","author":"NN Shah","year":"2024","unstructured":"Shah NN, Maziarz RT, Jacobson CA, et al. Interim results from a phase 2 pivotal study (DALY II USA) of tandem CD20-CD19-Directed Non-Cryopreserved CAR-T cells - Zamtocabtagene autoleucel (Zamto-Cel) in patients with Relapsed\/Refractory diffuse large B cell lymphoma. Blood. 2024;144(Supplement 1):68. https:\/\/doi.org\/10.1182\/blood-2024-208539.","journal-title":"Blood"},{"issue":"18","key":"765_CR69","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","volume":"5","author":"AF Herrera","year":"2021","unstructured":"Herrera AF, Ahn KW, Litovich C, et al. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021;5(18):3528\u201339. https:\/\/doi.org\/10.1182\/bloodadvances.2021004865.","journal-title":"Blood Adv"},{"issue":"1","key":"765_CR70","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100001","volume":"1","author":"ML Wang","year":"2022","unstructured":"Wang ML, Barrientos JC, Furman RR, et al. Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid. 2022;1(1):EVIDoa2100001. https:\/\/doi.org\/10.1056\/EVIDoa2100001.","journal-title":"NEJM Evid"},{"issue":"Supplement 1","key":"765_CR71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209610","volume":"144","author":"G Shouse","year":"2024","unstructured":"Shouse G, Popplewell L, Muir A, et al. Final update of safety, efficacy and T-cell predictive biomarkers from a phase I trial of Copanlisib\u2009+\u2009Nivolumab in patients with richter\u2019s transformation (RT) or transformed non-Hodgkin lymphoma (tNHL). Blood. 2024;144(Supplement 1):4484. https:\/\/doi.org\/10.1182\/blood-2024-209610.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00765-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00765-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00765-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:20:07Z","timestamp":1769044807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00765-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00765-y","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Henry Le, Ivan Huang, and Chloe Siu declare that they have no conflicts of interest. Grace Baek has received speaker honorarium from Postgraduate Healthcare, LLC, supported by a grant from Bristol Myers Squibb and completed an advisory board for AstraZeneca. Mazyar Shadman has the following conflicts: Consulting, advisory boards, steering committees or data safety monitoring committees: Abbvie, Genentech, AstraZeneca, Genmab, Janssen, Beigene, Bristol Myers Squibb,Morphosys\/Incyte, Kite Pharma, Eli Lilly, Fate therapeutics, and Merck. Research funding: Mustang Bio, Genentech, AbbVie, Beigene, AstraZeneca, Genmab, Sana Biotherapeutics, Morphosys\/Incyte.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}],"article-number":"21"}}